ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic
· RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies
Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” or “the Company”), a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, today announces the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed),FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and medical strategy and build its clinical development capabilities as the Company advances RBP-01, its lead programme for primary uveal melanoma, into the clinic.
